TÜREL, ÖzdenKisa, AdnanMcIntosh, E. David G.Bakir, Mustafa2020-10-222020-10-222013-07-01TÜREL Ö., Kisa A., McIntosh E. D. G. , Bakir M., -Potential Cost-Effectiveness of Pneumococcal Conjugate Vaccine (PCV) in Turkey-, VALUE IN HEALTH, cilt.16, ss.755-759, 2013http://hdl.handle.net/20.500.12645/24469https://www.sciencedirect.com/science/article/pii/S109830151301810X?via%3DihubBackground: Pneumococcal infection is an important and preventable cause of morbidity and mortality. The Turkish government introduced 7-valent pneumococcal conjugate vaccine (PCV) into the national immunization program in 2009. This suggests that replacing 7-valent PCV with a higher-valent version could at least maintain -standard of care- if not improve it, and that it could be affordable. Objectives and Methods: The aim of this analysis was to assess the potential direct cost-effectiveness of 13-valent PCV in Turkey, a country with a birth cohort of 1.4 million, against a -no vaccine- state, against the default 7-valent PCV state, and against a 10-valent PCV state, using a published cohort model with a 5-year horizon. Results and Conclusions: The cost per life-year gained is below the 1 x per-capita gross domestic product threshold across large changes in key input parameters, indicating that the model is stable and suggesting that any PCV would be very cost-effective in a Turkish national pediatric immunization schedule.info:eu-repo/semantics/openAccessVaccineArticleWOS:0003254666000088488166398410.1016/j.jval.2013.03.163223947968